Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol design for Recursion’s portfolio of clinical-stage drug candidates. 

Recursion, the leading clinical-stage TechBio company decoding biology to industrialize drug discovery, has made significant strides in recent months in advancing its end-to-end platform, spanning discovery, biology, chemistry, and clinical development. In November 2024, Recursion officially merged with Exscientia, resulting in a post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. As Recursion looks to advance these programs in 2025 and beyond, the company sought a technology partner aligned to Recursion’s mission of making drug discovery and development increasingly data-driven and efficient through AI/ML enabled platform technology. 

Faro Health offers the industry’s most advanced data-driven software platform for clinical protocol design, and is the only software platform to-date that has been proven to help sponsors reduce trial costs and complexity, while simultaneously minimizing burden to trial participants and sites. As part of this collaboration, Recursion will leverage Faro’s platform to optimize the protocol design of multiple upcoming clinical studies. In keeping with Recursion’s commitment to leveraging cutting-edge technology and AI-powered tools at every step of the drug discovery and development process, Recursion also anticipates further benefit from Faro’s platform as studies move from design to start-up, leveraging the structured study definitions created through Faro’s software to automate what have historically been highly manual and tedious downstream tasks, such as building the EDC (electronic data capture) system for each study.   

“To truly create better medicines for patients, we must place equal emphasis on leveraging data-driven and AI-powered solutions across both discovery and development,” said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. “At Recursion, we are committed to reimagining the entire process, and our partnership with Faro Health is a critical step in accelerating that vision. Together, we are embarking on a journey that goes beyond efficiency – it’s about unlocking new possibilities in how we design and execute clinical trials to bring transformative treatments to patients faster and more effectively”

Faro Health’s CEO, Scott Chetham, agreed, saying, “Recursion sees both the challenges and the opportunities in our industry in the same way we do at Faro. Drug development has only grown more expensive and time-intensive in the last several decades, even as computing power has become faster and cheaper. Recursion is leading the industry in reversing this trend, which makes them an ideal partner for Faro. We believe this collaboration will mark a pivotal turning point in our industry, and usher in an era of increasing efficiency in clinical development.”